VCG
AZN icon

Vantage Consulting Group’s AstraZeneca AZN Stock Holding History

Vantage Consulting Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40
Closed -$4K – 248
2020
Q4 		$4K Buy
+40
New +$4.24K ﹤0.01% 1468

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vantage Consulting Group's AZN Position: Q1 2021 in Review

Vantage Consulting Group sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 40 shares — an estimated $4K sold.

Vantage Consulting Group first reported a position in AZN in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 756 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Vantage Consulting Group reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 40 AstraZeneca shares in Q1 2021, an estimated $4K.
  • Vantage Consulting Group first reported a position in AstraZeneca in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's AstraZeneca position peaked at $4K in Q4 2020.
  • 756 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.